ABEO (Follow-Up)
Abeona Therapeutics Inc
Healthcare
09/20/2017
Presented
| Date | 09/15/2017 |
| Price | $17.20 |
| Market Cap | $0.69B |
| Ent Value | $0.62B |
| P/E Ratio | N/A |
| Book Value | $2.21 |
| Div Yield | 0% |
| Shares O/S | 40.30M |
| Ave Daily Vol | 572,651 |
| Short Int | 28.26% |
Current
| Price | $6.54 |
| Market Cap | $0.28B |
| Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas. |
Please note, this is an update to Abeona Therapeutics Inc (ABEO) - Long, which was last updated on July 18, 2017 ($8.95).
/////////////////////////////////////////////////////////////////
Publicly traded companies mentioned herein: Abeona Therapeutics Inc (ABEO), Regenxbio Inc (RGNX)
Highlights
The presenter remains long shares of Abeona Therapeutics (ABEO). On August 29th, the company announced that it had received FDA Breakthrough Therapy Designation (BTD) for EB-101, its cell therapy for recessive dystrophic epidermolysis Bullosa (RDEB). This is “quite important” to the company and his thesis because BTD accelerates the discussions with the FDA about EB-101 and can lead to an accelerated regulatory process. Thus, his estimates for EB-101’s contribution could be pulled forward by up to 12 months. Additionally, ABEO has scheduled its first R&D day on October 11, 2017, and investors should gain further insight into the plans for EB-101 and ABO-102 (the treatment of Sanfilippo syndrome type A). A lot of data are expected to be discussed, and with ABEO’s market cap recently surpassing $500mm he believes more investors are paying attention to the company (and starting to understand/ appreciate what is in the pipeline); “data on ABEO’s first two gene therapy programs look good thus far, and it could have five gene therapies in the clinic in 1Q 2018”.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.